XENON PHARMACEUTICALS INC (XENE)
Sector: Health Care
2026 Annual Meeting Analysis
XENON PHARMACEUTICALS INC · Meeting: June 2, 2026
Directors FOR
8
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Director since September 2016 with deep pharmaceutical commercialization experience; no overboarding (1 public board seat); the 3-year TSR trigger does not apply because Xenon's 3-year return of +48.2% exceeds the peer group median by +11.8 percentage points, well within the 65-percentage-point threshold for strong-positive TSR companies; no attendance issues or independence concerns.
Director since August 2023, which is within the 24-month new-director exemption window from the TSR trigger; holds 1 public board seat (Corcept Therapeutics), well below the overboarding threshold; strong pharmaceutical commercialization background relevant to Xenon's stage.
Director since May 2015 with extensive financial expertise (CPA, CA) as required for his Audit Committee Chair role; no public board seats outside Xenon; TSR trigger does not apply given Xenon's positive peer-relative outperformance over 3 years; no attendance or independence concerns.
Director since June 2021 with deep neurology and clinical development expertise directly relevant to Xenon's epilepsy and CNS pipeline; holds 2 public board seats (Acadia Pharmaceuticals, Alector), below the 4-seat overboarding threshold; TSR trigger does not apply; attended all committee meetings with only 1 board meeting missed out of 11.
Director since August 2023, within the 24-month new-director exemption; holds 1 public board seat (Compass Pathways); brings highly relevant epilepsy drug commercialization experience as former CEO of GW Pharmaceuticals; no independence or attendance concerns.
Director since November 2020 with senior biotech financial and business development experience; holds 2 public board seats (Alumis, Arcus Biosciences), below the 4-seat threshold; TSR trigger does not apply; missed 2 of 11 board meetings but attended all committee meetings, keeping aggregate attendance above the 75% threshold.
CEO and director since June 2021; as an executive director he is subject to the same TSR trigger as all other directors, but the trigger does not apply because Xenon outperformed the peer group median over 3 years by +11.8 percentage points; no overboarding (serves on no other public boards); his Say on Pay vote determination is handled separately.
Director since January 2004 with deep scientific and clinical expertise; holds no other public board seats; TSR trigger does not apply given peer-relative outperformance; attended all committee meetings with only 2 of 11 board meetings missed, keeping aggregate attendance above 75%.
All eight director nominees receive a FOR vote. Xenon's 3-year stock return of +48.2% outperforms the company-disclosed peer group median by +11.8 percentage points, far below the 65-percentage-point underperformance threshold that applies to strong-positive TSR companies, so no director is flagged on TSR grounds. No director is overboarded, no independence violations are present on audit or compensation committees, no familial relationships with senior management are disclosed, and all directors met the 75% meeting attendance threshold. Two newer directors (Cannon and Gover, both joining August 2023) also benefit from the 24-month new-director exemption.
Say on Pay
✓ FORCEO
Ian Mortimer
Total Comp
$9,221,712
Prior Support
96.3%%
CEO Ian Mortimer received total compensation of $9,221,712 in 2025, which is within a reasonable range for a CEO at a $5.4 billion biotech company with multiple late-stage clinical programs. The compensation structure is strongly performance-oriented: a meaningful portion of pay is delivered through stock options (which only have value if the share price rises), restricted stock units, and performance stock awards that vest only upon hitting predefined clinical and regulatory milestones — well above the 50-60% variable pay threshold required by policy. The pay-for-performance alignment check also passes: while Xenon's 1-year return lagged the XBI — SPDR S&P Biotech ETF by about 23 percentage points, its 3-year return of +48.2% outperforms the company-disclosed peer group median by +11.8 percentage points, and the prior year Say on Pay vote received 96.3% shareholder support, indicating strong investor satisfaction with the compensation program.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
PricewaterhouseCoopers LLP is a Big 4 firm appropriate for Xenon's $5.4 billion market cap. The proxy filing does not provide an auditor fee breakdown table from which audit and non-audit fees can be extracted, so the non-audit fee ratio trigger cannot be evaluated — per policy, the absence of confirmed fee data means the trigger does not fire and the default FOR vote applies. No material financial restatements are disclosed, and auditor tenure is not stated in the filing, so the tenure trigger also does not fire per policy.
Overall Assessment
The 2026 Xenon Pharmaceuticals annual meeting ballot is straightforward with no significant governance concerns triggering adverse votes. All eight director nominees receive a FOR vote because the company's stock has outperformed its peer group over three years, no director is overboarded or has independence issues, and attendance is adequate across the board; the Say on Pay proposal also receives a FOR vote given a well-structured performance-oriented compensation program, reasonable CEO pay for a $5.4 billion biotech, and an exceptionally strong 96.3% prior-year shareholder approval rate.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing